A-DONUT: Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection

Sponsor
Mount Sinai Hospital, Canada (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06004739
Collaborator
Sault Area Hospital (Other), Michael Garron Hospital (Other), Unity Health Toronto (Other), The Ottawa Hospital (Other)
550
2
48

Study Details

Study Description

Brief Summary

Delirium is an acute confusional state that is experienced by many older adults who are admitted to hospital. To treat delirium the underlying cause needs to be identified promptly, but this is challenging. One of the potential causes of delirium is infection. Urine tests show that most patients experiencing delirium have bacteria in their urine, however, bacteria in the urine is common among older adults, and does not automatically indicate an infection is present. As a result it is difficult to know whether a lower urinary tract infection is present as individuals with delirium are frequently unable to report clinical signs of infection - symptoms of pain or discomfort with urination, having to urinate more frequently or pelvic discomfort. Very often, individuals with delirium are treated with antibiotics despite the fact that it is unknown whether antibiotics help to improve delirium in cases where bacteria in the urine is present. This proposed study is a randomized controlled trial that will examine if adults (age 60 or older) with delirium and suspected infection benefit from taking antibiotics.

Condition or Disease Intervention/Treatment Phase
  • Drug: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria
  • Other: No Antibiotics for treatment of bacteriuria
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
550 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2027
Anticipated Study Completion Date :
Sep 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Other: Antibiotics

Participants will be randomized to start or continue with antibiotics. Antibiotic type and duration targeted to lower urinary tract infection as directed by the Most Responsible Physician (MRP).

Drug: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria
Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician [MRP]). Antibiotics choice to be selected by the MRP.

Other: No Antibiotics

Participants will be randomized to no antibiotics

Other: No Antibiotics for treatment of bacteriuria
Participants will be randomized to no antibiotics

Outcome Measures

Primary Outcome Measures

  1. Delirium at day 7 or at day of hospital discharge, whichever is earliest [Delirium will be assessed at the first of day 7 or discharge]

    Delirium will be assessed using Confusion Assessment Method (CAM) or 4 A's Test (4AT). CAM assesses 4 delirium features: [1] inattention, [2] acute and fluctuating level of consciousness, [3] disorganized thinking and [4] altered mental status. For a diagnosis of delirium by CAM, the patient must display feature [1] AND [2], AND EITHER [3] or [4]. The 4AT is scored from 0-12. A score of 4 or more suggests delirium.

Secondary Outcome Measures

  1. Length of hospitalization [Up to 30 days]

  2. Number of participants with bacteremia (bacteria isolated in blood culture) [Up to 7 days]

  3. Number of participants who were transferred to Intensive Care Unit (ICU) [Up to 7 days]

  4. Number of participants who had a fall [Up to 7 days]

  5. Number of participants who were physically restrained [Up to 7 days]

  6. Number of participants who received antipsychotics [Up to 7 days]

  7. Days of antibiotics [Up to 7 days]

  8. Number of participants with C. difficile infection [By 30 days]

    C. difficile will be defined as a combination of a positive microbiological test for C. difficile (if still hospitalized at the time of diagnosis), or self-reported diagnosis of C. difficile (provided the patient reported diarrhea and receipt of an antibiotic to treat C. difficile)

  9. Number of participants who died [By 30 days]

  10. Number of participants who died [By 365 days]

  11. Number of participants who were readmitted to hospital [By 365 days]

  12. Number of participants who were readmitted to hospital [By 30 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion criteria

  • Age ≥ 60 and admitted to a hospital ward (including rehabilitation hospital);

  • Active delirium (defined by CAM: [1] inattention AND [2] acute and fluctuating level of consciousness, and either [3] disorganized thinking OR [4] altered mental status; or defined by the 4AT score [www.the4at.com/]) OR physician's diagnosis

  • Less than 24 hours of antibiotics (prior to trial assessment)

  • Either pyuria (defined as white blood cells detected on urinalysis or dipstick) or bacteriuria (defined as bacteria growing on urine culture)

Exclusion criteria

  • Fever (temperature > 37.9C or > 100.2F) in the past 48 hours;

  • Signs of lower urinary tract infection symptoms (such as new dysuria) or upper urinary symptoms (such as costovertebral tenderness)

  • In the opinion of the treating physician, there is a reason apart from delirium and urine test results to treat with antibiotics (e.g., pneumonia)

  • Indwelling urinary catheter for > 72 hours

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Mount Sinai Hospital, Canada
  • Sault Area Hospital
  • Michael Garron Hospital
  • Unity Health Toronto
  • The Ottawa Hospital

Investigators

  • Principal Investigator: Michael Fralick, MD, PhD, Sinai Health System
  • Principal Investigator: Chris Kandel, MD, PhD, Michael Garron Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mount Sinai Hospital, Canada
ClinicalTrials.gov Identifier:
NCT06004739
Other Study ID Numbers:
  • CTO 4466
First Posted:
Aug 22, 2023
Last Update Posted:
Aug 22, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mount Sinai Hospital, Canada
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2023